Q4 2024 · 13F-HR
Sarissa Capital Management LPholdings as filed
Filed 2025-02-14 · accession 0000899140-25-000321
$322.9M
Reported value
8
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 45781M101 | INVA | INNOVIVA INC | $126.3M | 39.1% | 7,277,000 | Common | SOLE |
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $72.6M | 22.5% | 16,390,000 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $42.2M | 13.1% | 309,116 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $39.2M | 12.1% | 833,799 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $24.2M | 7.50% | 262,080 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $12.1M | 3.73% | 24,850,623 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HLDGS INC | $5.6M | 1.75% | 63,000 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $685,980 | 0.21% | 618,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.